Panacea Biotec Ltd Stock Price Today (NSE: PANACEABIO)
Fundamental Score
Panacea Biotec Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Panacea Biotec Ltd share price today is ₹419.40, down 0.49% on NSE/BSE as of 4 August 2026. Panacea Biotec Ltd (PANACEABIO) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹3.30K (Cr). The 52-week high for PANACEABIO share price is ₹647.00 and the 52-week low is ₹292.40. The company has a Return on Equity (ROE) of -2.36% and a debt-to-equity ratio of 0.03.
Panacea Biotec Ltd Share Price Chart — NSE/BSE Historical Performance
Panacea Biotec Ltd share price chart: -22.39% return over the past month. 52-week high ₹647.00, 52-week low ₹292.40.
Panacea Biotec Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹425.05 | ₹425.05 | ₹415.60 | ₹423.45 | 71.01K (Cr) | |
| ₹414.00 | ₹434.00 | ₹413.25 | ₹421.45 | 1.58L (Cr) | |
| ₹425.00 | ₹429.40 | ₹406.40 | ₹414.45 | 1.12L (Cr) | |
| ₹422.00 | ₹426.00 | ₹415.10 | ₹423.85 | 1.32L (Cr) | |
| ₹428.05 | ₹433.95 | ₹411.45 | ₹414.40 | 1.94L (Cr) | |
| ₹442.60 | ₹447.25 | ₹431.05 | ₹433.10 | 1.25L (Cr) | |
| ₹440.00 | ₹449.00 | ₹433.00 | ₹441.20 | 1.73L (Cr) | |
| ₹551.95 | ₹560.95 | ₹494.00 | ₹494.00 | 6.70L (Cr) | |
| ₹552.00 | ₹553.00 | ₹538.85 | ₹548.85 | 1.11L (Cr) | |
| ₹565.50 | ₹565.55 | ₹540.10 | ₹548.85 | 2.17L (Cr) |
Panacea Biotec Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹425.05 | ₹425.05 | ₹415.60 | ₹423.45 | -0.38% | |
| ₹565.50 | ₹597.00 | ₹406.40 | ₹421.45 | -25.47% | |
| ₹402.10 | ₹647.00 | ₹391.00 | ₹565.85 | +40.72% | |
| ₹360.20 | ₹439.20 | ₹360.20 | ₹412.85 | +14.62% | |
| ₹307.00 | ₹385.00 | ₹307.00 | ₹361.05 | +17.61% | |
| ₹317.40 | ₹365.00 | ₹292.40 | ₹296.05 | -6.73% | |
| ₹368.05 | ₹382.90 | ₹327.55 | ₹331.00 | -10.07% | |
| ₹379.50 | ₹448.00 | ₹342.40 | ₹372.95 | -1.73% | |
| ₹367.55 | ₹433.95 | ₹322.65 | ₹376.30 | +2.38% | |
| ₹440.00 | ₹443.95 | ₹341.50 | ₹367.60 | -16.45% | |
| ₹410.95 | ₹464.00 | ₹398.50 | ₹437.90 | +6.56% | |
| ₹416.60 | ₹474.25 | ₹393.10 | ₹406.90 | -2.33% |
AI Research Briefing
Powered by Gemini · 2026-04-13
Low-quality vaccine supplier trading on order flow, not fundamentals.
WHAT'S HAPPENING NOW (last 2-4 weeks)
Panacea Biotec secured a contract from the Central Medical Services Society (CMSS) on April 10, 2026, to supply Diphtheria and Tetanus Vaccine. Supplies are slated to begin in September/October 2026 and conclude by November/December 2028. The company also received four awards from the Industrial Tribunal, S.A.S. Nagar, Mohali, regarding workmen transfer, wage revision, and reinstatement matters.
CORE STORY (THE REAL GAME)
Panacea Biotec is a vaccine play, leveraging government contracts and international agreements (like UNICEF) for revenue. The focus is on securing orders and executing vaccine supply, not necessarily on high-margin innovative products.
- ₹20.79 crore order win from CMSS
- Existing UNICEF contracts provide revenue visibility
- Sector tailwinds from India Pharma 2026
- New, larger government contracts
- Successful DengiALL vaccine development
- Improved profitability and cash flow
- Negative ROE/ROCE/OPM
- High reliance on government contracts
- Small-cap liquidity risk
FII/DII increased stake slightly (Δ 0.27%/0.28%), but overall institutional holding remains low.
Government policy push for pharma innovation, but supply chain issues and high costs remain headwinds.
₹20.79 crore contract from CMSS for Diphtheria and Tetanus Vaccine.
No: Free Cash Flow 5Y: ₹-603.42 Cr.
Reliance on government contracts and international agreements for revenue. Focus on securing orders and executing vaccine supply.
Primary Thesis Risk
Reliance on low-margin government contracts and poor financials.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Panacea Biotec Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Panacea Biotec Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of PANACEABIO across key market metrics for learning purposes.
Positive Indicators
5 factors identified
Robust Profit Growth (93.02%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (25.82%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Conservative Debt Levels (D/E: 0.03)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Balanced Promoter Holding (72.48%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
8 factors identified
Below-Average Return on Equity (-2.36%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (-2.44%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Margin Pressure Concerns (-5.56%)
Observation: Operating margins are below industry standards.
Analysis: OPM <5% may indicate pricing pressures or cost management challenges.
Limited Growth History (0.47% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Weak Interest Coverage (-3.44x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Negative Free Cash Flow (₹-728.50 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Limited Institutional Interest (FII+DII: 3.56%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Panacea Biotec Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Panacea Biotec Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Panacea Biotec LtdPanacea Biotec ...Selected✓ PANACEABIO • 531349 | 36.2/100 | ₹419.40₹419 | ₹3296.20₹3296.20 | — — | -2.36%Poor -2.36% Poor | -2.44%Poor -2.44% Poor | 0.03Excellent 0.0 Excellent | 13.30%Good 13.30% Good | 0.47%Average 0.47% Average | 0.00% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1990.50₹1991 | ₹468821.49₹468821.49 | 37.73Average 37.7 Average | 15.95%Good 15.95% Good | 20.53%Excellent 20.53% Excellent | 0.06Excellent 0.1 Excellent | 16.75%Excellent 16.75% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 56.3/100 | ₹8056.00₹8056 | ₹193163.97₹193163.97 | 73.64Average 73.6 Average | 16.53%Good 16.53% Good | 21.96%Excellent 21.96% Excellent | 0.00Excellent 0.0 Excellent | 5.71%Good 5.71% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹5122.80₹5123 | ₹169902.02₹169902.02 | 77.52Average 77.5 Average | 27.43%Excellent 27.43% Excellent | 15.19%Good 15.19% Good | 1.79Average 1.8 Average | 12.07%Good 12.07% Good | 11.80%Good 11.80% Good | 0.76% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 40.2/100 | ₹1473.20₹1473 | ₹116131.81₹116131.81 | 30.51Average 30.5 Average | 11.60%Average 11.60% Average | 15.49%Good 15.49% Good | 0.02Excellent 0.0 Excellent | 9.94%Good 9.94% Good | 8.01%Good 8.01% Good | 0.90% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1078.30₹1078 | ₹115375.77₹115375.77 | 21.26Average 21.3 Average | 21.25%Excellent 21.25% Excellent | 21.14%Excellent 21.14% Excellent | 0.46Excellent 0.5 Excellent | 18.77%Excellent 18.77% Excellent | 12.45%Good 12.45% Good | 0.09% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 83.4/100 | ₹2415.00₹2415 | ₹113976.53₹113976.53 | 20.04Average 20.0 Average | 28.68%Excellent 28.68% Excellent | 29.93%Excellent 29.93% Excellent | 0.29Excellent 0.3 Excellent | 37.02%Excellent 37.02% Excellent | 13.02%Good 13.02% Good | 0.72% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2469.60₹2470 | ₹105053.91₹105053.91 | 52.29Average 52.3 Average | 13.12%Average 13.12% Average | 13.50%Average 13.50% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 41/100 | ₹1148.10₹1148 | ₹102660.46₹102660.46 | 25.62Average 25.6 Average | 11.22%Average 11.22% Average | 13.04%Average 13.04% Average | 0.20Excellent 0.2 Excellent | 15.44%Excellent 15.44% Excellent | 12.09%Good 12.09% Good | 0.65% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1580.20₹1580 | ₹90035.87₹90035.87 | 25.38Average 25.4 Average | 10.06%Average 10.06% Average | 12.80%Average 12.80% Average | 0.21Excellent 0.2 Excellent | 0.80%Average 0.80% Average | 6.32%Good 6.32% Good | 0.26% |
Laurus Labs LtdLaurus Labs Ltd... LAURUSLABS • 540222 | 34.1/100 | ₹1816.20₹1816 | ₹84016.75₹84016.75 | 93.94Average 93.9 Average | 18.30%Good 18.30% Good | 17.76%Good 17.76% Good | 0.48Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price468821.49 Cr
- Divis Laboratories Ltd share price193163.97 Cr
- Torrent Pharmaceuticals Ltd share price169902.02 Cr
- Cipla Ltd share price116131.81 Cr
- Zydus Lifesciences Ltd share price115375.77 Cr
Panacea Biotec Ltd PE Ratio History
Historical price-to-earnings ratio for PANACEABIO — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2022 | ₹176.05 | ₹142.05 | 0.8x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Panacea Biotec Ltd Quarterly Performance
Latest quarterly metrics for PANACEABIO — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
25.82%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
93.02%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
0.47%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
13.30%
Compounded annual net profit growth over 5 years
Panacea Biotec Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for PANACEABIO — calculated from daily price history
Selling pressure is heavy — potential reversal zone.
Technical indicators are for educational purposes only. Not investment advice.
Panacea Biotec Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Panacea Biotec Ltd (PANACEABIO) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Panacea Biotec Ltd
About PANACEABIO (Panacea Biotec Ltd)
Panacea Biotec Ltd is a pioneering pharmaceutical and biotechnology powerhouse, driven by a commitment to innovation and a healthier world. Carving a niche for itself, the company'...s core focus lies in the development, manufacturing, and commercialization of a diverse range of healthcare solutions, spanning from life-saving vaccines to a spectrum of complex pharmaceutical formulations. Beyond pharmaceuticals, Panacea Biotec also explores the realm of nutraceuticals, recognizing the importance of nutrition in promoting overall wellness. With state-of-the-art research and development facilities, the company remains dedicated to pushing the boundaries of medical science, seeking to create impactful products that address unmet healthcare needs globally. Operating across both domestic and international markets, Panacea Biotec organizes its activities strategically into two primary business segments: Vaccines and Pharmaceutical Formulations & Nutrition. The Vaccines segment focuses on developing and producing a range of prophylactic vaccines, crucial for preventing infectious diseases and safeguarding public health. Simultaneously, the Pharmaceutical Formulations & Nutrition segment encompasses a broad array of therapeutic products, catering to a variety of medical conditions. This includes prescription medications designed to target diseases like diabetes, support gastrointestinal function, aid in orthopedic recovery, and manage pain. Panacea Biotec's expansive product portfolio stands as a testament to its dedication to holistic healthcare solutions. Through diligent research, technological advancements, and strategic partnerships, the company continues to expand its offerings, striving to improve patient outcomes and contribute to a healthier future. Its commitment to quality, innovation, and patient-centricity has established Panacea Biotec as a key player in the pharmaceutical and biotechnology landscape, consistently working towards making a positive impact on global health and well-being.
Company Details
Key Leadership
Corporate Events
PANACEABIO Share Price: Frequently Asked Questions
What is the current share price of Panacea Biotec Ltd?
Panacea Biotec Ltd (PANACEABIO) trades at ₹419.40 on NSE and BSE. Market cap ₹3.30K (Cr). Educational data only.
What is the P/E ratio of Panacea Biotec Ltd?
Panacea Biotec Ltd has a P/E of N/Ax vs industry average 34.89x.
What is the Bull Run score for Panacea Biotec Ltd?
Panacea Biotec Ltd has a Bull Run score of 36.2/100 based on 25+ financial parameters.
Does Panacea Biotec Ltd pay dividends?
Panacea Biotec Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Panacea Biotec Ltd?
Panacea Biotec Ltd has ROE of -2.36%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Panacea Biotec Ltd?
Panacea Biotec Ltd has debt-to-equity of 0.03.
Is Panacea Biotec Ltd a good investment?
Bull Run gives Panacea Biotec Ltd a score of 36.2/100. This is not investment advice — consult a SEBI-registered advisor.